The clinical value of exhaled nitric oxide in patients with lung cancer
The clinical value of exhaled nitric oxide in patients with lung cancer
复制标题
DOI：
10.1111/crj.12471
复制
发表时间：
2018-01-01
影响因子：
1.7
通讯作者：
Xie, Li-Xin
中科院分区：
文献类型：
--
作者：
Liu, Peng-Fei;Zhao, Da-Hui;Xie, Li-Xin
目的探讨呼气部分一氧化氮(FeNO)在肺癌患者中的临床价值。方法选择172例健康对照组和164例经组织病理证实的肺癌患者。FeNO测量和肺功能测试在解放军总医院进行。结果肺癌患者血清eNO水平显著高于健康对照组(33.85±15.63 ppb，n=163；16.83±/-4.17 ppb，n=172；P
Introduction and ObjectivesTo investigate the clinical value of fractional exhaled nitric oxide (FeNO) in lung cancer patients.Methods A total of 172 healthy control subjects and 164 patients with histopathologically confirmed lung cancer were enrolled in this study. The FeNO measurements and pulmonary function tests were conducted in the Chinese PLA General Hospital. The recorded data included FeNO, the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC), FEV1/FVC, the FEV1 (% predicted), the demographic characteristics, the presence of complications and the smoking status.Results The patients with lung cancer had a significantly higher level of eNO than the healthy control subjects (33.8515.63 ppb, n=163; 16.83 +/- 4.17 ppb, n=172; P